Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Down – Should You Sell?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $152.82, but opened at $138.58. Palvella Therapeutics shares last traded at $140.9660, with a volume of 6,917 shares trading hands.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PVLA. Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday. HC Wainwright upped their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Stephens reiterated an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Finally, Chardan Capital reissued a “buy” rating and set a $240.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Price Performance

The stock has a fifty day simple moving average of $120.67 and a 200-day simple moving average of $111.93. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -35.19 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, equities analysts expect that Palvella Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the sale, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors have recently modified their holdings of the business. Avidity Partners Management LP raised its holdings in Palvella Therapeutics by 262.7% in the 1st quarter. Avidity Partners Management LP now owns 70,000 shares of the company’s stock worth $8,726,000 after purchasing an additional 50,700 shares during the period. Arete Wealth Advisors LLC acquired a new stake in Palvella Therapeutics in the first quarter valued at approximately $2,178,000. Bank of America Corp DE grew its holdings in Palvella Therapeutics by 25.4% in the first quarter. Bank of America Corp DE now owns 37,972 shares of the company’s stock valued at $4,733,000 after purchasing an additional 7,700 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Palvella Therapeutics by 688.9% in the first quarter. The Manufacturers Life Insurance Company now owns 17,907 shares of the company’s stock valued at $2,232,000 after buying an additional 15,637 shares in the last quarter. Finally, First Light Asset Management LLC increased its position in shares of Palvella Therapeutics by 38.3% in the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after buying an additional 271,617 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.